IntelliCell BioSciences selects inVentiv Health Clinical as CRO for osteoarthritis IND
inVentiv Health Clinical has been selected by IntelliCell BioSciences, a regenerative medicine company, as contract research organization (CRO) for conducting a clinical trial in osteoarthritis of the knee under an Investigational New Drug (IND) application.
Dr James Andrews will act as principal investigator for the study. Dr Andrews is a founding partner and medical director for the Andrews Institute in Gulf Breeze, Florida. He is also a founding member of the American Sports Medicine Institute.
In association with inVentiv Clinical, IntelliCell BioSciences and Dr Andrews are developing the investigational clinical study protocols.
The clinical trial will be conducted at the Pensacola Center of the Andrews' Research and Educational Institute (AREI). The study will be conducted in conjunction with AREI prominent physicians Dr Adam Anz and Dr Josh Hackel.
Until now, IntelliCell's technology for isolating stromal vascular fraction cells from the vasculature of adipose tissue has been used to successfully treat over 60 knees with results lasting as long as five years.
IntelliCell BioSciences CEO Dr Steven Victor noted this is a pivotal point for the company as it will be what the company believes to represent the first of many clinical trials that the company will undertake and establish the company as a leader in the cellular therapy segment of the biotech industry.
"This IND study is important for proving the company's patented technology of Ultrasonic Cavitation as a method of separating stromal vascular fraction cells from lipoaspirate. We believe that IntelliCell's Stromal Vascular Fraction Cells will offer people with OA a new and improved approach to gaining significant improvements in their qualities of life.
"We at IntelliCell are excited to have this opportunity to work with the distinguished Sports Medicine Orthopedic Surgeon, Dr. James Andrews, who will be the principal investigator of this clinical trial," Dr Victor added.